

Positive PD-L1 expression			
Clinical Features	n	Tumor	Stroma
Stage I	24	3 (12)	5 (21)
Stage II	19	7 (37)	11 (58)
Stage III	21	14 (67)	17 (81)
Stage IV	32	27 (91)	31 (97)
Chemoresistant	51	44 (86)	37 (73)
Chemosensitive	45	19 (43)	22 (48)
Metastatic	47	35 (74)	31(66)
Non-metastatic	49	17 (35)	12 (24)

Table S7. Proportion of positive PD-L1 protein expression in lung cancer patients as determined by immunohistochemical analysis. Numbers in parenthesis indicate percentiles (%) in the total population of patients.